Currently Enrolling Clinical Trials

Sitravatinib (MGCD516)

Sponsored by Mirati

Study 516-002:
Phase 2 study of sitravatinib in combination for clear cell renal cell cancer
Study 516-003:
Phase 2 study of sitravatinib in combination with a checkpoint inhibitor for urothelial carcinoma
Study 516-005:
Phase 3 study of sitravatinib in combination with nivolumab for non-small cell lung cancer (NSCLC) (SAPPHIRE)
Study 516-008:
Phase 1/1b study of sitravatinib in combination with nivolumab and ipilimumab

KRAS G12C Inhibitor Adagrasib (MRTX849)

Sponsored by Mirati

Study 849-001:
Phase 1/2 study of MRTX849 in patients with cancer having a KRAS G12C mutation (KRYSTAL-1)
Study 849-002:
Phase 1/2 study of MRTX849 in combination with TNO-155 in patients with cancer having a KRAS G12C mutation (KRYSTAL-2)
Study 849-007:
Phase 2 study of MRTX849 in combination with pembrolizumab in NSCLC patients having a KRAS G12C mutation (KRYSTAL-7)
Study 849-010:
Phase 3 study of MRTX849 with cetuximab vs chemotherapy in patients with CRC with KRAS G12C mutation (KRYSTAL-10)
Study 849-012:
Phase 3 study of MRTX849 vs docetaxel in patients with NSCLC with KRAS G12C mutation (KRYSTAL-12)

Collaborative Trials

Sponsored by Mirati in collaboration with industry partners.

BeiGene Sponsored Trials

Study BGB-900-103:
Phase 1b study of sitravatinib in combination for advanced solid tumors
Study BGB-900-104:
Phase 1/2 study of sitravatinib monotherapy and in combination for HCC or GC/GEJC

This information is not intended to replace the informed medical advice or medical treatments of a health care professional. Only a physician can decide if a specific medicine is the correct treatment for a particular patient or whether enrollment in a clinical trial is appropriate. If you have questions about treatment of your medical condition, consult a qualified health care professional.

To identify clinical trials that match your diagnosis, treatment history and location, call 1-844-893-5530 or use our online Study Locator.